Wednesday, 25 March 2020

Biological drugs for SLE


An imaginary drug for Convid 19: Biologic drugs:- -What ate Biologic drugs??  Top of Form
·         There are some disease modifying drugs designated as DMRD .These drugs are sometimes used in Rh arthritis, Renal Lupus  and modifies Cytokines , Throbaxane -1 etc.
Some drugs of this broad family (Biologic Drugs)  are A) TNF alpha antagonists like intercept, Ifiixicam, adalimumab which suppress some reactions in the body .May be tried in Guinea pig if Ethics Committee approves after intentionally infecting the animal with the covid-19  Virus..But I am not sure whether such Lab animals are susceptible to Convid 19.
·         https://static.xx.fbcdn.net/rsrc.php/v3/yA/r/_ZvGTxrlsmm.png?_nc_eui2=AeHhkMTuAMyIOs1AqKZDqt07JXSGG_icKXCC6WD0ydLJ7E73RHfMqTa73tt1sHSxi58BVNwOeOu45fVt5-nWKw2Fhf59E9jwA8w6A0Q51AWTrQ These group of drugs block the pro inflammatory cytokines and may save the human lungs from severe damage..
·         https://static.xx.fbcdn.net/rsrc.php/v3/yA/r/_ZvGTxrlsmm.png?_nc_eui2=AeHhkMTuAMyIOs1AqKZDqt07JXSGG_icKXCC6WD0ydLJ7E73RHfMqTa73tt1sHSxi58BVNwOeOu45fVt5-nWKw2Fhf59E9jwA8w6A0Q51AWTrQ  Assuming that we need urgent shift of Th 1 to Th 2 at alveolus  and protect the lungs tissue against NK cells abrupt rise  at alveolus. As a corollary can we implement what is called “Biologic Therapy” as we do in Rec Implantation failure or to improve endometrial sensitivity ?
·         I am not sure .These are just imaginations. But lung parenchyma protective drugs are need of the hour.: There are drugs which cause B cell depletion ( Rituxmab ) . The other biologic agents use may be considered in Lab animals , if Ethics Committee approves) is TOCILIZUMAB(ANTI-interleukin 6 receptor antibody) & yet another biologic agent is Belimumab ( a human monoclonal antibody that inhibits B cell activating factor. Edit or delete this
o    Like
o     · Reply
o     · 1m

Top of Form
Write a comment...


·        

·        

·        

·        

Bottom of Form
Bottom of Form
OLDER




No comments:

Post a Comment